Fen-Phen (fenfluramine + phentermine) — the Diet-Drug Craze Yanked in 1997 for Wrecking Heart Valves

When the U.S. Food and Drug Administration asked American Home Products to pull fenfluramine (Pondimin) and dexfenfluramine (Redux) from the market on 15 September 1997, it ended a weight-loss phenomenon that had been built on an off-label pairing the agency had never approved and a long-term safety record nobody had assembled. Fen-Phen — the colloquial yoking of fenfluramine, a serotonin-releasing anorectic approved in 1973, with phentermine, a stimulant approved in 1959 — had become, by 1996, one of the most prescribed drug ideas in America: roughly 18 million prescriptions in that year alone and an estimated 6 million users, exposure on the order of 61 million patient-months. The gap between the promise of easy, doctor-blessed thinness and the harm was a class of damage that does not announce itself: scarred heart valves and, more rarely, lethal pulmonary hypertension.

The combination’s popularity rested on a 1992 study and on a regulatory permission slip that was never granted. The FDA had approved fenfluramine and phentermine each as standalone short-term anorectics; it had never approved their combination, nor either drug for the open-ended, cosmetic, multi-year use that fen-phen clinics dispensed. The 1996 approval of dexfenfluramine — the more potent right-handed isomer, sold as Redux and the first new prescription weight-loss drug in 23 years — poured accelerant on the market, despite an FDA advisory committee that had initially voted against it and known pulmonary-hypertension concerns in European data.

The verdict is plain at the outset. A combination the agency never sanctioned, marketed for a use it never authorized, reached millions before any long-term cardiac safety study existed; the damage was found not by the regulator or the manufacturer but by Mayo Clinic cardiologists who noticed a pattern. Their report, published in the New England Journal of Medicine on 28 August 1997, described 24 women with no prior cardiac history who had developed an unusual valvular disease — leaflets thickened with a glistening, carcinoid-like plaque — after taking fen-phen. The drug came off the market eighteen days later.

What followed was, for its era, the largest product-liability reckoning in pharmaceutical history. American Home Products (renamed Wyeth in 2002) agreed to a $3.75 billion national class settlement in 1999, then watched its total liability climb past $21 billion as tens of thousands of plaintiffs opted out, and the case became the standard byword for what happens when an off-label combination and a direct-to-consumer obesity market outrun the safety science that should have preceded them.

Permax (pergolide) — the Parkinson’s Drug Pulled in 2007 for Quintupling Heart-Valve Damage

When the U.S. Food and Drug Administration announced on 29 March 2007 that the makers of pergolide had agreed to pull the drug from the American market, the action was filed as a routine post-market safety measure; the documented record shows that the fibrotic heart-valve mechanism that condemned Permax had been understood, in chemical detail, for years before the echocardiograms were read. Pergolide (marketed by Eli Lilly as Permax and approved by the FDA in 1988 as an adjunct to levodopa for Parkinson’s disease) was an ergot-derived dopamine agonist that relieved tremor and rigidity by stimulating dopamine receptors — but it also bound potently to the 5-HT2B serotonin receptor on heart-valve tissue, the identical target that had driven the valvulopathy behind the 1997 fen-phen catastrophe.

The gap between promise and harm was not an unforeseeable side effect. Two studies published side by side in The New England Journal of Medicine on 4 January 2007 closed the case. René Schade and colleagues, mining the U.K. General Practice Research Database cohort of 11,417 patients, found that pergolide carried an adjusted incidence-rate ratio of 7.1 (95% CI 2.3-22.3) for newly diagnosed cardiac-valve regurgitation. Renzo Zanettini’s echocardiographic study found clinically important (moderate-to-severe) regurgitation in 23.4 percent of pergolide patients versus 5.6 percent of controls — and, decisively, 0 percent in patients on non-ergot dopamine agonists, which do not hit the 5-HT2B receptor.

The verdict is therefore plain at the outset: a drug with no proven efficacy advantage over safer, mechanistically distinct alternatives kept hundreds of thousands of Parkinson’s patients exposed to a known fibrotic hazard years after the signal was legible. The FDA asked Lilly to add valvulopathy to the warnings section in 2003 and mandated a boxed warning in 2006; neither step removed the drug. Only the 2007 NEJM pair forced a withdrawal the pharmacology had argued for since at least 2002 — a quieter case than the blockbuster scandals, with no settlement fund and no Senate hearing, only a back-of-the-shelf agent kept in front-line use long after a receptor profile shared with a recalled diet drug had told clinicians exactly where to look.